Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

@article{Shanker2015BortezomibIA,
  title={Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.},
  author={Anil Shanker and Samuel Troy Pellom and Duafalia Fred Dudimah and Menaka C Thounaojam and Rachel De Kluyver and Alan David Brooks and H. Yagita and Daniel W McVicar and William J. Murphy and Dan L. Longo and Thomas Joseph Sayers},
  journal={Cancer research},
  year={2015},
  volume={75 24},
  pages={5260-72}
}
Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well, such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Because T cells provide multiple death ligands at the tumor site, we investigated the effects of bortezomib on T-cell responses in immunotherapy models involving low-avidity antigens. Bortezomib did not… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Mitochondrial-mediated disregulation of Ca2þ is a critical determinant of Velcade Bortezomib Enhances Cancer Immunotherapy www.aacrjournals.org Cancer Res

  • TH Landowski, CJ Megli, KD Nullmeyer, RM Lynch, RT. Dorr
  • on October
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…